LumiraDx Limited (NASDAQ:LMDX) Sees Large Increase in Short Interest
LumiraDx Limited (NASDAQ:LMDX) Sees Large Increase in Short Interest
LumiraDx Limited (NASDAQ:LMDX – Get Rating) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 309,800 shares, a growth of 14.7% from the October 31st total of 270,100 shares. Approximately 2.1% of the company's stock are short sold. Based on an average daily volume of 337,500 shares, the days-to-cover ratio is currently 0.9 days.
LumiraDx Limited(納斯達克:LMDX-GET評級)是11月份空頭股數大幅增長的接受者。截至11月15日,空頭股數共有309,800股,較10月31日的270,100股增長14.7%。該公司約有2.1%的股票被賣空。根據日均成交量337,500股計算,目前天數與回補比率為0.9天。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several equities analysts have recently weighed in on LMDX shares. Raymond James decreased their price objective on LumiraDx from $4.00 to $3.50 and set an "outperform" rating for the company in a report on Friday, November 11th. BTIG Research decreased their price objective on LumiraDx from $7.00 to $4.00 and set a "buy" rating for the company in a report on Friday, August 19th.
幾位股票分析師最近紛紛買入LMDX的股票。雷蒙德·詹姆斯在11月11日星期五的一份報告中將LumiraDx的目標價從4.00美元下調至3.50美元,併為該公司設定了“跑贏大盤”的評級。BTIG Research將LumiraDx的目標價從7.00美元下調至4.00美元,並在8月19日星期五的一份報告中為該公司設定了買入評級。
LumiraDx Price Performance
LumiraDx性價比
Shares of NASDAQ LMDX opened at $1.29 on Friday. The stock has a market capitalization of $58.36 million, a price-to-earnings ratio of -0.91 and a beta of 1.05. The business has a 50-day moving average of $1.09 and a 200-day moving average of $1.88. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42.
上週五,納斯達克LMDX的股價開盤報1.29美元。該股市值為5,836萬美元,市盈率為-0.91,貝塔係數為1.05。該業務的50日移動均線切入位在1.09美元,200日移動均線切入位在1.88美元。該公司的債務權益比為20.12,流動比率為2.91,速動比率為1.63。LumiraDx的52周低點為0.77美元,52周高位為10.42美元。
Hedge Funds Weigh In On LumiraDx
對衝基金參與LumiraDx
LumiraDx Company Profile
LumiraDx公司簡介
(Get Rating)
(獲取評級)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家醫療診斷公司。該公司專注於通過向醫療保健提供者提供關鍵診斷信息來轉變基於社區的醫療保健。它製造和銷售一種診斷平臺,該平臺支持各種測試,在護理點具有實驗室可比的性能。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免費獲取StockNews.com在LumiraDx(LMDX)上的研究報告
- 為什麼CSL有限公司的股票值得一看
- MarketBeat:回顧一週11/28-12/02
- Okta Inc.慶祝收益節節攀升,但他們能持續這種提振嗎?
- 機構正在購買安巴雷拉,你應該嗎?
- ZIM能否抵禦集裝箱航運業的普遍低迷?
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對LumiraDx和相關公司的最新新聞和分析師評級的每日簡要摘要。